125 filings
6-K
GMAB
Genmab
21 Dec 20
Current report (foreign)
10:25am
6-K
GMAB
Genmab
15 Dec 20
Current report (foreign)
5:17pm
6-K
GMAB
Genmab
24 Nov 20
Genmab Announces Enapotamab Vedotin Update
11:59am
6-K
GMAB
Genmab
12 Nov 20
Current report (foreign)
9:54am
6-K
GMAB
Genmab
10 Nov 20
Capital Increase in Genmab as a Result of Employee Warrant Exercise
3:04pm
6-K
vzlpmzrfkqp
5 Nov 20
Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
11:06am
6-K
xr7rlvhfhnxm uovi
4 Nov 20
Genmab Announces Financial Results for the First Nine Months of 2020
11:48am
6-K
gfoqj 7wc
21 Oct 20
Current report (foreign)
5:06pm
6-K
8h7bexj azw
15 Oct 20
Current report (foreign)
11:09am
6-K
bcpyn
14 Oct 20
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2020
4:54pm
6-K
t07cou
7 Oct 20
Current report (foreign)
5:15pm
6-K
gied ytycb
30 Sep 20
Current report (foreign)
2:06pm
6-K
njeg33
30 Sep 20
Current report (foreign)
10:49am
6-K
4pqwdby fyrv
30 Sep 20
Current report (foreign)
12:00am
6-K
cwn bzgffmt0
29 Sep 20
Capital Increase in Genmab as a Result of Employee Warrant Exercise
4:02pm
6-K
ukfi2f7lgy0j
22 Sep 20
Genmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen
5:14pm
6-K
aj39il
20 Aug 20
Current report (foreign)
5:29pm
6-K
thn9 c83p7qut
20 Aug 20
Current report (foreign)
5:24pm
6-K
ynkx01i8t idd
20 Aug 20
U.S. FDA Approves Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
2:19pm
6-K
h753cvbftcln
19 Aug 20
Current report (foreign)
10:59am